Inventiva, a French biopharmaceutical company focused mainly on fibrosis, announced Monday the extension of an agreement with AbbVie Inc. (ABBV), a research-based biopharmaceutical company, to continue discovery and development efforts for orally available small molecule ROR? inverse agonist drug candidates.
In addition, to the ongoing work in preclinical discovery and development, the company announced that ABBV-553, AbbVie's current ROR-? inverse agonist lead compound, will cease development following a Phase 1 study.
Under the terms of the agreement, Inventiva will receive an undisclosed research payment. Additionally, Inventiva will receive milestone payments when a new candidate is identified. Inventiva will also be eligible for development and sales milestones as well as royalties on sales.
Pierre Broqua, Inventiva Co-Founder and Chief Scientific Officer, said, "Inventiva continues to leverage its knowledge and expertise in ROR? development and around nuclear receptors and transcription factors. ROR? is one of the most promising small molecule approaches in controlling the production of T helper 17 cells, with the potential to treat several autoimmune diseases."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.